valve cleft, right ventricular wall hypertrophy, fetal bradycardia, dextroaortic arch.
OBJECTIVES Mycoplasma pneumoniae (M. pneumoniae) primarily causes upper respiratory tract infection and atypical pneumonia in school-aged children. Mycoplasma-associated Cardiac involvement such as acute myocarditis, or pericarditis isan uncommon complication occurring in only less than 5% of patients. In this report, We report one case with acute pericarditis due to M. pneumoniae in our hospital over 5 year period.
METHODS Retrospective analysis was performed on 60 patients (<14 years old) with serologically confirmed M. pneumoniae presenting to the emergency department from January 2009 to March 2015. Among them, one patient developed acute pericarditis due to M. pneumoniae infection.
RESULTS
This 8 year old boy was admitted to the emergency department in July 2009 with a 6 day history of fever up to 38.5 C, cough, wheeze, vomiting and lethargy. He had been started on oral clarithromycin by pediatric clinic for one day.On the second hospital day, the patient developed shortness of breath, obvious chest pain, oliguria and the fever increased up to 39 C. His rate of heart was up to 147bpm. Blood pressure was 76/51mmHg. the pericardial friction rub could be heard at his precordium region and lung auscultation revealed coarse rhonchi and wheezes. Blood test results showed His hemoglobin levels at 11.0 g/dL; leukocyte count was 8700/mL; platelets count was 215000/mL; aspartate aminotransferase was 132 IU/L; alanine transaminase was 145 IU/L; creatinine kinase (CK) was 476 IU/ L; CK-MB was 124 ng/mL; pro-brain natriuretic peptide (pro-BNP) was 5218 pg/mL; lactate dehydrogenase level was 420 IU/L; erythrocyte sedimentation rate was 14 mm/h; C-reactive protein was 19 mg/L; and ELISA test for M. pneumoniae IgM was positive (1:800), influenza virus (A and B), respiratory syncytial virus, adenovirus, parainfluenza virus, Chlamydia pneumoniae, legionella pneumophila, Coxsackie A, Coxsackie B, and echovirus antibodies were negative. Abdominal hepatobiliary ultrasound was normal. Chest radiograph showed signs of bronchopneumonia. Echocardiogram showed mild pericardial effusion, normal left ventricle contractility. Based on these findings, mycoplasma pneumonia complicated by acute pericarditis with pericardial effusion were diagnosed. We treated the patient with intravenous azithromycin 10 mg/kg/day and intravenous immunoglobulin, diuretics, dopamine, Antileukotriene agents, nebulized bronchodilators and corticosteroid (ICS). on the next few days, the child's symptoms of lower respiratory tract gradually improved and became afebrile in four days, CK-MB and pro-BNP had gradually improved to normal. Pericardial effusion had disappeared in two weeks.
CONCLUSIONS M. pneumoniae may be the pathogen of acute pericarditis patients. Appropriate and timely treatment is required. Serological testing for Mycoplasma pneumoniae should be part of the routine examination for pericarditis of unknown Origin.
GW26-e4631
Prenatal diagnosis of ductus arteriosus constriction: report of six cases and review of the literature METHODS The databases were searched for all cases of ductal constriction detected during the last 3 years. The following variables were analyzed: gestational age at diagnosis, indication for echocardiography, presence of right ventricular hypertrophy, presence of tricuspid valve regurgitation, ductal pulsatility index, signs of fetal heart failure, pregnancy and feto-neonatal outcome, and ductal status at neonatal echocardiography.
RESULTS Six cases of fetus were presented with tricuspid valve regurgitation secondary to an S-shaped ductus arteriosus with distal constriction diagnosed by pulsed Doppler imaging. None of the cases were secondary to maternal exposure to indomethacin or other nonsteroidal anti-inflammatory medications, or structural cardiac lesions. A review of the recent English literature of similar cases is presented.
CONCLUSIONS Constriction of the ductus arteriosus can be diagnosed prenatally with careful interrogation of the ductal arch using pulsed Doppler sonography and complete fetal echocardiography. Close monitoring of the fetus is then warranted to detect development of right heart failure and to intervene prior to development of hydrops.
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GW26-e1564
Angiotensin blockades are associated with a lower mortality in patients with atrial fibrillation: results from a national wide atrial fibrillation database Juan Wang, Jun Zhu, Han Zhang, Xinghui Shao, Bi Huang, Huaibin Wan, Yanmin Yang Emergency and Intensive Care Center, Fuwai Hospital, Chinese Academy of Medical Science and Peking Union Medical College OBJECTIVES Few studies have investigated the effects of angiotensin blockades (ABs) on mortality and cardiovascular events of established patients with atrial fibrillation (AF). Aim of the current study was to assess the association between ABs treatment and 1-year survival in patients with AF in real-world clinical practice.
METHODS The present study consecutively enrolled AF patients presenting to an emergency department at 20 hospitals in China from November 1, 2008 to October, 31 2011. Multivariate Cox proportional hazards regression was used on all the patients. End points of the analyses were all-cause mortality, stroke and major adverse events (MAE).
RESULTS A total of 2015 AF patients were included in the analysis, and 42.2% patients received ABs treatment. During 1-year follow-up, 13.8% patients died. In the final multivariate Cox proportional models of predictors for all-cause mortality and stroke, after adjustment for multiple relevant co-variables, ABs was significantly associated with a lower risk of all-cause mortality (HR: 0.66, 95% CI: 0.50-0.88, p¼0.004) compared to non-ABs patients. Meanwhile, ABs was not an independent risk factor for stroke (HR: 0.81, 95% CI: 0.56-1.19, p¼287).
CONCLUSIONS ABs usage was associated with a lower all-cause mortality in patients with AF, as well as it did not increase the risk of stroke and MAE incidences.
GW26-e0266
Safety and effectiveness of Tadalafil on PAH from a post-marketing surveillance (Investigation on all patients in Japan, interim data) from ongoing All-patient Investigation in patients with pulmonary arterial hypertension (PAH).
METHODS 818 case report forms from patients receiving tadalafil were collected from December 2009 (the drug launch time) to October 2013. The observation period was up to 2 years. 815 eligible patients data was analyzed for safety and 765 PAH patients data was analyzed for effectiveness. WHO functional classification of PAH and 6-minute walking test were used to evaluate effectiveness. The study was conducted in accordance with the Good Post-marketing Study Practice (GPSP) Ministerial Ordinance.
RESULTS
The major patient characteristics were: median age (45.4 years), female (67.7%), and patient receiving tadalafil for PAH treatment (93.9%). 37.7% patients were with idiopathic PAH (IPAH), 2.0% were familial PAH (FPAH), and 53.5% were associated with other diseases (APAH) such as collagen vascular diseases (28.0%) and congenital systemic-to-pulmonary shunts (23.9%). 31.17% of the patients developed drug-related treatment-emergent adverse events (TEAEs) such as headache (8.83%), epistaxis (2.33%) and diarrhea (2.21%), which is consistent with the existing safety profile. As for effectiveness, patients who improved more than 1 class of WHO functional classification (e.g. from Class II to Class I) were: 16.1% (120/ 744) after 3 months treatment, 25.6% (73/285) after 12 months, and 32.4% (34/105) after 24 months. While patients who worsened over 1 class (e.g. from Class I to II) were: 1.5% (11/744) after 3 months, 1.4% (4/285) after 12 month, and 4.8% (5/105) after 24 months. At the end of observation (24 months since the administration), 6-minute walking distance (6MWD) of 52 cases was increased by 51.7 m (mean distance change, 95% CI, 23.0 -80.4 m).
CONCLUSIONS The interim analysis of the All-Patient Investigation suggests that no new safety concerns were identified in patients receiving long-term tadalafil treatment in daily clinical practice. Based on the results of effectiveness analysis, in spite of limited numbers of cases evaluated, improvement in effectiveness was noted in the course of tadalafil treatment.
GW26-e5447
Evaluation of thienopyridine-resistance in Indian patients by measuring platelet aggregation in post-PCI patients receiving antiplatelet medication: Outcomes with 'AggreGuide A-100' platelet aggregometer Rajasekhar Durgaprasad, Vanajakshamma Velam, Madhavi Rodda, Boochi Babu Mannuva, Vidyasagar Akula, Latheef Kasala Sri Venkateswara Institute of Medical Sciences (SVIMS), India OBJECTIVES In the current era of interventions, monitoring the effectiveness of antiplatelet medications is vital. Considering the emergence of antiplatelet resistance, reduced response to antiplatelet therapy may leads to the stent thrombosis which is associated with high morbidity and mortality. In the present study we evaluated the effectiveness of thienopyridine-based antiplatelet regimens in post-PCI patients using AggreGuide A-100 platelet aggregometer (Aggredyne Inc., USA), a new, FDA-approved, easy-to-use, point-of-care device developed to monitor platelet aggregation in whole blood using laser-light scattering technique.
METHODS In this prospective, single-center study, patients whoreceived antiplatelet therapy after undergoing coronary stent implantation at an Indian tertiary care center during May-October, 2014 were enrolled. Platelet aggregation was evaluated from the blood sample of each study participant after 2-3 days of antiplatelet therapy using the AggreGuideA-100. Test results were obtained as platelet activity index (PAI), on a scale ranging from 0 to 10. Since the PAI value <2 is obtained as no detectable aggregation during the test, such observations were assigned the PAI value of 2. Test findings were interpreted as (a) therapy working ifthe PAI value is 2-5 and (b) therapy not working if the PAI value is above 5.
RESULTS A total of 220 patients (mean age: 55.35AE9.51 years; 74.5% males) were enrolled in the study. Among the study group, 79 (35.9%), 100 (45.5%), and 41 (18.6%) patients received Clopidogrel-, Prasugrel-, and Ticagrelor based antiplatelet therapy respectively, at the discretion of the treating physician. The AggreGuide A-100 testing indicated that the effectiveness of antiplatelet therapy was inadequate in 43 (19.5%) patients. In particular, 30 (38.0%) patients receiving Clopidogrel-, 11 (11.0%) patients receiving Prasugrel-, and 2 (4.9%) patients receiving Ticagrelor-based antiplatelet therapy displayed inadequate platelet response. Antiplatelet therapy was optimized accordingly for these patients.
CONCLUSIONS Monitoring individual's platelet activity should become a new standard-of-care for patients on antiplatelet therapy.
Using AggreGuide A-100, nearly 20% of patients were identified to have inadequate response to thienopyridine-based antiplatelet therapy in our study. Antiplatelet therapy was optimized accordingly for these patients with inadequate response.
GW26-e0691
Variability of ticagrelor antiplatelet responsiveness in Chinese ACS patients Tong Yin, Xuyun Wang, Jia Liu, Yundai Chen Department of Cardiology, General Hospital of Chinese People's Liberation Army, Beijing China OBJECTIVES Ticagrelor provides more consistent, rapid, and potent platelet inhibition than clopidogrel, however, the interindividual variability in response to ticagrelor was not absent. This study sought to display the various distribution of ticagrelor antiplatelet responsiveness in Chinese acute coronary syndrome (ACS) patients.
METHODS Consecutive Chinese-Han patients with ACS who received maintenance dose of ticagrelor (90 mg, bid) and aspirin (100 mg, qd) were recruited from General Hospital of Chinese People's Liberation Army. After 5 days ticagrelor maintenance treatment, 5umol/L ADP induced residue platelet aggregation (RPA) by light transmittance aggregometry (LTA), and platelet inhibition (PI ADP ) measured by thrombelastography (TEG) were measured.
RESULTS
Overall, 532 ACS patients (Male: 72.56%, Age: 60AE11 years) under ticagrelor maintenance treatment were recruited. Antiplatelet responsiveness measured by LTA was available in 146 patients, and by TEG in 176 patients. After 5 days' ticagrelor maintenance dose therapy, the value of RPA measured by LTA was (13.87AE9.41)% on average (range from 1.80% to 51%). With the pre-specific cutoffs for HTPR (5umol/L ADP induced RPA >40%), 4 patients (2.74%) were identified as HTPR. The value of PRA < 10% could be seen in fifty-six patients (38.36%). The value of PI ADP measured by TEG was (85.92AE17.79)% on average (ranged from 4.80% to 100%). The distribution curve of both RPA and PI ADP values moved to the direction of strong antiplatelet responsiveness with the possibility of increased risk for bleeding.
CONCLUSIONS The variability of ticagrelor antiplatelet responsiveness could be detected in Chinese ACS patients. Association of the ticagrelor antiplatelet responsiveness variability to clinical efficacy and safety outcomes should be evaluated in the future.
GW26-e1537
Ticagrelor overcomes high on-clopidogrel treatment platelet reactivity in patients with acute myocardial infarction or coronary artery in-stent restenosis: a randomized controlled trial Pan Li, Yawei Yang, Tao Chen, Yu Liu, Junmei Liu, Xianxian Zhao, Yongwen Qin, Liping MA. Department of Cardiology, Changhai Hospital, Second Military Medical University OBJECTIVES High on-treatment platelet reactivity (HTPR) after clopidogrel therapy is accompanied by an increased risk of adverse outcomes. Direct comparison between ticagrelor and high-dose clopidogrel has not yet been reported in patients with acute myocardial infarction (AMI) or coronary artery in-stent restenosis (ISR).
METHODS In a prospective, single-center, single-blind, randomized trial, consecutive patients with AMI or coronary artery ISR treated with standard-dose clopidogrel (75 mg/day) were screened with the VerifyNow assay, defining HTPR as P2Y12 reaction units (PRUs) >208. Of the 102 screened patients, 48 (47.06%) patients with HTPR were randomly assigned to either ticagrelor (180 mg/90 mg twice daily) or high-dose clopidogrel (150 mg/day) for 24 hours.
RESULTS Baseline characteristics and mean PRUs were similar in both groups. After 24 hours, ticagrelor was associated with a significantly lower platelet reactivity than high-dose clopidogrel (44.38 AE 40.26 vs. 212.58 AE 52.34 PRU, P<0.05) . No patient receiving ticagrelor exhibited HTPR, whereas 15 (62.50%) patients after treatment with high-dose clopidogrel remained HTPR (P<0.05). During the follow-up (mean, 138.42 AE53.59 days), no patient exhibited a major bleeding event in either treatment group.
CONCLUSIONS The prevalence of HTPR is high in patients with AMI or coronary artery ISR after standard clopidogrel treatment. Ticagrelor is significantly more effective compared with high-dose clopidogrel in overcoming HTPR.
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